ESMO 2022

Hand cooling and compression both effective in…

Dose dense is better

Long-term data on dose density therapy in chemotherapy

Reduction of peripheral neuropathy with taxane therapy

Immuntherapy only for low risk patients?

Dose-dense standard of care is the optimal care

Simple and cheap surgical technique may impact survival…

QoL and longterm toxicity

Dose-dense therapy is beneficial for all patients

Consolidating data from prospective studies

Roadmap for the adjuvant setting

My highlights of ESMO22

DD is the champion!

Schéma dose-dense bénéfique pour toutes les patientes

Rosta i tania technika chirurgiczna może wpływać na…

Chłodzenie rąk i terapia kompresyjna skutecznie…

Il vincitore e’ il dose dense!!

I miei punti salienti di ESMO22

DATA: Still open questions on the optimal duration of…

Dose-dense CT Efficacy confirmed in the Nodal+ ER+…

Status update - adjuvant IO. Are TILs prognostic?

How to deal with the negative SERD data?

Unmeet needs and my wishes for 2022!

Who needs Chemo? Who does not? Is OFS plus endocrine…

Survival benefit in endocrine sensitive patients

Sacituzumab govitecan for everybody!

More therapy options for patients with HR+, HER2+…

Another option for heavily pre-treated HR+ advanced…

New treatment option for heavily pre-treated patients…

Discontinued development

OS not significant, but re-assuring new data

The third in the bunch

CDK4/6i could be an option for selected ER+/HER2+…

Update on biomarkers on ADCs of the DAISY trial

HER2+ and still without chemotherapy

Exciting data, but Phase 3 studies are needed

Negative and yet positive?!

SG is a novel treatment option for HR+/HER2- disease

TROPiCS-02 highlights

Interim analysis shows promising data on Abema in the…

Endocrine-based therapy may prove more effective than…

VEX has no place in chemotherapy of metastatic breast…

New data re-inforces SG as a new option pre-treated…

Survival benefit from SG in mBC

My highlights of ESMO22

Nuove opzioni di trattamento personalizzate per…

Survie globale pas encore significative statistiquement…

TROPiCS-02 highlights

Leczenie zaawansowanych raków „potrójnie dodatnich”…

Nouvelles données des analyses expolratoires dans…

Nouvelle option thérapeutique pour les patientes…

I miei punti salienti di ESMO22

Sopravvivenza globale nello studio MONARCH3

Sacituzumab Govitecan: Un farmaco per tutte?

Interim OS Data & PFS Update for Abemaciclib hint…

SG confirms benefit in OS, PFS, ORR, QoL, the new 2nd…

CDK4/6i plus Trastuzumab – a possible chemo-free option…

SERDs: equal PFS benefit vs. endocrine therapy;…

ADC efficacy in perspective: SG overall survival…

Concurrent preoperative IO/CRT in early lung cancer

ADAURA revisited

Double IO + chemoradiotherapy - is it feasible in…

Long term follow-up of ADAURA trial

Is OS really needed?

INCREASE - to good to be true?

Pollution and lung cancer - one mechanism revealed

Neoadjuvant strategies for PD-L1 < 1 %

Osimertinib - curing or delaying relapse?

Osimertinib stays standard adjuvant

Window for treatment selection

Liquid biopsy monitoring of EGFR-mutant lung cancer…

Liquid biopsie monitoring van patiënten met een EGFR…

Langzeitdaten ADAURA

ADAURA revisited

Osimertinib bleibt Standard adjuvant

Eine Plattform für "take the winner"-Strategie

Pollution et cancer du poumon - un mécanisme mis en…

Osimertinib: una cura o ritarda la ripresa di malattia?

DFS matters!

Long term follow-up of KEYNOTE-189 and KEYNOTE-407

Sotorasib vs. Docetaxel in mKRAS G12C

DESTINY-Lung02 - better than the original?

Sotorasib - a new standard of care?

Preview on lung cancer highlights

A new step in treatment of KRAS G12C mutant NSCLC

Pneumonitis and T-DXd

Can we finally treat poor prognostic patients with…

Cemiplimab beyond progression?

Real-world data on Atezolizumab

HER2 - the next actionable mutation in lung cancer?

New immunotherapy options for pts. ineligible to 1st…

Induction chemoimmunotherapy in borderline…

Chemoimmunotherapy - improvement of survival after 5…

Sotorasib: sweet and sour results

5-year update on 1st line chemoimmunotherapy

5-year data on survival under immunotherapy

Poseidon and STK11/KEAP

5 years of chemoimmunotherapy: solid grounded

Liquid biopsy monitoring in treatment decisions

Emerging IO mono options in the first line

Question about timing and duration of immunotherapy…

One more brick in the KRAS G12C wall

The journey at KRAS G12C continues

New therapy combination after progression on 1L…

Is shorter immunotherapy equally effective and less…

Atezolizumab better than vinorelbin in reduced…

Duration of immunotherapy : Stop and go strategy for…

If you don't look, vou don't find - once you found it,…

Immunotherapy in unfit population? Perhaps...

Kürzere Immuntherapie gleich effektiv aber weniger…

5 Jahre Chemo-Immuntherapie: starker Effekt

Atezo besser als Vino bei PS2-3

Sotorasib vs. Docetaxel bei mKRAS G12C

Pneumonitis und T-DXd

Neue Therapiekombination in der Resistenz nach…

Cemiplimab beyond progression?

Chimio-immunothérapie - amélioration de la survie après…

Poseidon und STK11/KEAP

Données de vie réelle avec l’atezolizumab

Liquid Biopsy Monitoring zur Therapiesteuerung

Les études incontournables à l’ESMO 2022

Une nouvelle étape dans le traitement du CBNPC KRAS…

Kunnen we eindelijk patiënten met een slechte prognose…

Neue Option der IO-Therapie in der Erstlinie

Die Reise bei KRAS G12C geht weiter

5-Jahresüberleben mit Immuntherapie

Una nueva opción de tratamiento con IO en pacientes no…

Resultados Agridulces de Sotorasib

Un mattone in piu' nel muro del KRAS G12C

Chemo-IO-Induktion bei grenzwertiger Resektabilität?

IO-IO neoadjuvant bei PD-L1 neg.

Se non lo cerchi non lo troiv. Quando lo hai trovato,…

Durée de l'immunothérapie : stratégie Stop and Go pour…

Kann IO pausiert werden?

A positive study! With a question mark?

Heterogenity in the genetic landscape - little progress…

Novel data and long-term efficacy of chemo-IO in mNSCLC

Adjuvant CPI in kidney cancer – 2 phase III trials with…

No value of IPI/Nivo in the adjuvant setting.

News in terms of adjuvant

Place of triplet therapy

New combo - triplet therapy for kidney cancer

Exciting data for high-risk patients: is this the start…

Immune-based peri-operative treatment in RCC: What went…

Adjuvant Immuntherapy in kidney cancer

Two negative studies question adjuvant approach in RCC

More questions being raised

Inmunoterapia adyuvante en el cancer renales

Μηνύματα από το ESMO22 για τον καρκίνο του νεφρού

Tratamiento perioperatorio con immunoterapia en cáncer…

Immunomodulation in combination with…

Therapy combinations in RCC - what is the role of…

Shedding light on TKI/Checkpointinhibitor combinations

EV + Pembro with excellent response rates

Brief highlights about RCC & urothelial cancer from…

Promising data, but beware of toxicity

Adjuvant and neoadjuvant therapy approaches in…

IO + PARP without benefit in the allcomer situation

In older vulnerable - less is more

Combination of olaparib leads to promising results

IM arbiraterone decanoate might demonstrate superior…

ADCs - a possible therapeutic approach

Biomarker data for better patients selection

Cabazitaxel better tolerated in elderly men

Update on the PROpel study

Genetic testing before PARP therapy is useful

Radicals - ADT & Radiotherapy

Length of hormone therapy after radiation

Should intensification of ADT be considered in…

ADT + ENZA better choice than monotherapy

Further evaluation of PSA correlates

PSA at 8-months as a biomarker

Optimizing cabazitaxel chemotherapy

Triplet therapy with darolutamide in prostate cancer

Uppdatering i PROpel studien

Livskvalitetsuppföljning i ARASENS studien

Which men benefit from adding ADT?

Positive results, but testing not that simple

Modern Imaging is the new standard

PSA response after triplet therapy: What is the impact…

Addition of CPI to Radiochemotherapy in LA-HNSCC?

IAP-inhibition – comming game changer in LA-HNSCC…

New group of substances for rare diseases

Novel approach von Biontech towards Cancer – game…

TILs - Fashion is the eternal return of the old